| Title |
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
|
|---|---|
| Published in |
Vascular Health and Risk Management, February 2016
|
| DOI | 10.2147/vhrm.s89130 |
| Pubmed ID | |
| Authors |
Tiffany Y Hu, Vaibhav R Vaidya, Samuel J Asirvatham |
| Abstract |
Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant effect. In a recent Phase III study (Reversal Effects of Idarucizumab on Active Dabigatran), a 5 g intravenous infusion of idarucizumab resulted in the normalization of dilute thrombin time in 98% and 93% of the two groups studied, with normalization of ecarin-clotting time in 89% and 88% patients. Two other antidotes, andexanet alfa (PRT064445) and ciraparantag (PER977) are also under development for reversal of NOACs. In this review, we discuss commonly encountered management issues with NOACs such as periprocedural management, laboratory monitoring of anticoagulation, and management of bleeding. We review currently available data regarding specific antidotes to NOACs with respect to pharmacology and clinical trials. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 29% |
| Japan | 1 | 7% |
| United Kingdom | 1 | 7% |
| Canada | 1 | 7% |
| Qatar | 1 | 7% |
| Malaysia | 1 | 7% |
| Unknown | 5 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 50% |
| Practitioners (doctors, other healthcare professionals) | 6 | 43% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Slovenia | 1 | <1% |
| Unknown | 148 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 15% |
| Other | 18 | 12% |
| Student > Bachelor | 18 | 12% |
| Student > Doctoral Student | 17 | 11% |
| Researcher | 16 | 11% |
| Other | 33 | 22% |
| Unknown | 27 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 79 | 52% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 7% |
| Agricultural and Biological Sciences | 9 | 6% |
| Nursing and Health Professions | 5 | 3% |
| Chemistry | 5 | 3% |
| Other | 7 | 5% |
| Unknown | 35 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2016.
All research outputs
#4,279,808
of 25,374,917 outputs
Outputs from Vascular Health and Risk Management
#139
of 804 outputs
Outputs of similar age
#69,730
of 406,425 outputs
Outputs of similar age from Vascular Health and Risk Management
#2
of 12 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,425 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.